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Pancreatic ductal adenocarcinoma (PDAC) will soon belong to the top
three cancer killers. The only approved specific PDAC therapy targets the
epidermal growth factor receptor (EGFR). Although EGFR is a crucial
player in PDAC development, EGFR-based therapy is disappointing. In
this study, we evaluated the role of the EGFR ligand betacellulin (BTC) in
PDAC. The expression of BTC was investigated in human pancreatic
cancer specimen. Then, we generated a BTC knockout mouse model
by CRISPR/Cas9 technology and a BTC overexpression model. Both mod-
els were crossed with the Ptf1aCre/+;KRASG12D/+ (KC) mouse model
(B/KC or BKC, respectively). In addition, EGFR, ERBB2, and ERBB4
were investigated by the pancreas-specific deletion of each receptor using
the Cre-loxP system. Tumor initiation and progression were analyzed in all
mouse lines, and the underlying molecular biology of PDAC was investi-
gated at different time points. BTC is expressed in human and murine
PDAC. B/KC mice showed a decelerated PDAC progression, associated
with decreased EGFR activation. BKC mice developed severe PDAC with
a poor survival rate. The dramatically increased BTC-mediated tumor bur-
den was EGFR-dependent, but also ERBB4 and ERBB2 were involved in
PDAC development or progression, as depletion of EGFR, ERBB2, or
ERBB4 significantly improved the survival rate of BTC-mediated PDAC.
BTC increases PDAC tumor burden dramatically by enhanced RAS activa-
tion. EGFR signaling, ERBB2 signaling, and ERBB4 signaling are
involved in accelerated PDAC development mediated by BTC indicating
that targeting the whole ERBB family, instead of a single receptor, is a
promising strategy for the development of future PDAC therapies.
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1. Introduction
With a 5-year survival rate of 8% pancreatic ductal
adenocarcinoma (PDAC) is worldwide one of the
deadliest cancers. While mortality rates are declining
for many cancers due to early detection and improved
treatment, rates for PDAC are still rising (Siegel et al.,
2018), promoting PDAC to the top three cancer killers
within the next decade (Rahib et al., 2014). Standard
PDAC treatment includes surgical resection and adju-
vant chemotherapy with FOLFIRINOX or gemc-
itabine in combination with nab-paclitaxel providing
the most promising results (Aslan et al., 2018). How-
ever, systemic chemotherapy is associated with severe
side effects. There is an urgent need to find customized
therapies targeting aberrantly regulated molecules in
PDAC. Over 95% of PDAC patients harbor an acti-
vating point mutation in the Kirsten rat sarcoma viral
oncogene homolog (KRAS) gene (Bryant et al., 2014).
KRASG12D is the initiating mutation in PDAC being
detected in over 90% of pancreatic intraepithelial neo-
plasia (PanIN) (Fischer and Wood, 2018). Attempts to
target aberrant KRAS in PDAC were promising in
preclinical studies. However, their performance in clin-
ical trials was rather disappointing (Zeitouni et al.,
2016). A further challenge is the limited delivery of
therapeutics to the cancer cells in the stroma of
PDAC, which has a high extracellular matrix content
and shows poor vascularization (Olive, 2015). It was
shown that the epidermal growth factor receptor
(EGFR), acting upstream of KRAS, was required for
oncogenic KRAS-driven PDAC tumorigenesis in mice
with a wild-type tumor protein 53 (Tp53) background
(Ardito et al., 2012; Navas et al., 2012). Indeed,
EGFR is the only molecule approved for targeted
PDAC therapy in the clinic, albeit with marginal
improvement in survivalwith only a small subset of
patients responding. Surprisingly, the response rate to
erlotinib in PDAC patients is independent of the pan-
creatic EGFR expression status (Moore et al., 2007).
Thus, many questions concerning EGFR signaling in
PDAC remain to be addressed. EGFR belongs to the
family of the ERBB receptors as ERBB2 (HER2, neu),
ERBB3 (HER3), and ERBB4 (HER4). They homo- or
heterodimerize upon ligand-dependent activation in
order to induce cellular responses like proliferation,
migration, apoptosis, differentiation, and adhesion,
and with 28 possible receptor combinations (including
spliced receptors) and 11 ligands (Schneider and Wolf,
2009), the family is able to induce 611 different active
receptor/ligand combinations (Roskoski, 2014). Many
ERBB ligands like EGF and transforming growth
factor alpha (TGFA) (Wagner et al., 1998), amphireg-
ulin (AREG) (Wang et al., 2016), heparin-binding
EGF-like growth factor (HBEGF) (Ray et al., 2014),
and epiregulin (EREG) (Zhu et al., 2000) have been
associated with PDAC. While all of them bind EGFR,
a subset also binds ERBB4, indicating that EGFR
might not be the only candidate to mediate their
effects in PDAC. A further EGFR- and ERBB4-bind-
ing ligand, betacellulin (BTC) has also been associated
with PDAC. BTC mRNA was detected in human pan-
creatic cancer cell lines (hPaCaCells) and elevated in
human PDAC tissues (Yokoyama et al., 1995). BTC
was also revealed to be a potent mitogen in hPaCa-
Cells, while the transmitting receptors remained
unidentified (Kawaguchi et al., 2000). This is particu-
larly interesting since its designated receptor ERBB4
plays controversial roles in PDAC development and
progression (Graber et al., 1999; Kolb et al., 2007;
Mill et al., 2011). The role of ERBB4 seems to be con-
text-dependent, probably due to its—in contrast to its
ERBB relatives—ability to signal in form of its soluble
intracellular domain (ICD80) after undergoing regu-
lated intramembrane proteolysis (RIP) (Carpenter,
2003), induced by tumor necrosis factor alpha convert-
ing enzyme (Kenny and Bissell, 2007). However, in
another pancreatic disorder BTC transgenic mice were
protected against acute pancreatitis mediated by
ERBB4 signaling and independent of EGFR (Hedeg-
ger et al., 2019). This demonstrates the complexity of
the ERBB system and points out the versatile
responses to ERBB ligands in a tissue-specific manner.
There is an urgent need to unravel the intricate ERBB
network in pancreatic cancer to better understand not
only the role of EGFR, but also to show the potential
significance of its relatives in order to establish more
efficiently targeted therapies. To investigate BTC in
pancreatic cancer, we generated a BTC knockout
mouse model (BTC/) and overexpressed BTC in a
transgenic mouse model (Btctg/+). Both models were
crossed in a PDAC mouse model, and to assess the
receptor dependency, BTC-transgenic mice were also
crossed with PDAC mouse lines with pancreas-specific
EGFR, ERBB2, or ERBB4 deletions.
2. Materials and methods
2.1. Human samples
For ERBB receptor immunohistochemistry (IHC), pri-
mary PDACs that were resected between 2008 and
2013 at the Klinikum rechts der Isar, Technische
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Universit€at M€unchen, were used after written informed
consent was obtained. Pancreatic samples from nondis-
eased pancreas served as controls. The use of this
patient cohort for biomarker analysis has been
approved by the ethics commission of the Klinikum
Rechts der Isar, Technische Universit€at M€unchen
(403/17S), and the study methodologies conformed to
the standards set by the Declaration of Helsinki.
2.2. Animals
All animal experiments were approved by the author’s
institutional committee on animal care and carried out
in accordance with the German Animal Protection
Law with permission from the responsible veterinary
authority (Az.:55.2-1-54-2532-26-2014). Mice carrying
floxed Egfrfl/fl (Egfrtm1Dwt) (Lee and Threadgill, 2009),
Erbb2fl/fl(Garratt et al., 2000), Erbb4fl/fl (B6;129-Erb-
b4tm1Fej/Mmucd) (Long et al., 2003), and KrasG12D/+
(B6.129S4-Krastm4Tyj/J)(Jackson et al., 2001) alleles or
expressing Cre recombinase under the pancreas-specific
transcription factor 1 alpha (Ptf1a-Cre) (Ptf1atm1(cre)
Hnak) (Nakhai et al., 2007) promoter have been
described previously. Transgenic mouse lines ubiqui-
tously overexpressing BTC under the control of the
chicken-beta-actin gene promoter (Btctg/+) have been
described elsewhere (Schneider et al., 2005). We cross-
mated Btctg/+;Ptf1aCre/+;KrasG12D/+ (herein referred to
as BKC) mice and Btctg/+;Ptf1aCre/+;KrasG12D/+;Egfrfl/
fl, Btctg/+;Ptf1aCre/+;KrasG12D/+;Erbb2fl/fl, and Btctg/+;
Ptf1aCre/+;KrasG12D/+;Erbb4fl/fl mice (herein referred to
as E1KO;BKC, E2KO;BKC, and E4KO;BKC, respec-
tively) to delete the designated ERBB receptor pan-
creas-specifically using the Cre-loxP-system. The
genotypes of all mice were verified by PCR (Qiagen,
Hilden, Germany), employing genomic DNA from tail
tips by using the oligonucleotides listed in Table S1.
Mice were maintained in the C57BL/6N background
and housed under specific pathogen-free conditions in
the closed barrier facility of the Gene Center Munich
at 23 °C, 50% humidity, and with a 12-h light/dark
cycle (lights on at 7 AM). They had free access to
water and a standard rodent diet (V1534, Ssniff, Soest,
Germany). Mice were weighed weekly until the age of
6 months and afterwards, still weekly or every
2 weeks. Mice were killed at the designated time points
or, for survival analysis, were left alive and killed as
soon as they became moribund.
2.3. Generation of BTC knockout mice (BTC/)
For CRISPR/Cas9-assisted Btc gene disruption using
a single guide RNA (sgRNA) specific for exon 2
sequence 50-GTCTTGCAATTCTCCACTGTG-30, a
corresponding oligonucleotide was cloned into the
pEX-A-U6-gRNA vector as described previously
(Dahlhoff et al., 2017). Cas9 mRNA and sgRNA were
in vitro-transcribed by using the Ambion Maxiscript
SP6 kit (Thermo Fisher Scientific, Waltham, MA,
USA). C57BL/6N zygotes were injected with Cas9
mRNA (50 ngµL1) and sgRNA (100 ngµL1), and
embryos were transferred into recipient NMRI mice.
Potential founders were identified by PCR using the
primers listed in Table S1. Based on the detected
mutations, a PfiMI restriction fragment length poly-
morphism assay was established, yielding fragments of
210 and 290 bp for wild-type Btc and a single frag-
ment of 500 bp for the mutated Btc sequence. Two
founder animals with monoallelic insertions of 1 bp
were identified. The insertion of 1 bp leads to a shift
in the reading frame in Btc exon 2. The mutated Btc
transcripts encode 27 amino acids (aa) of the extracel-
lular BTC domain, followed by a 31 aa missense
sequence and a premature termination codon after 58
aa (Fig. S1).
2.4. Pancreas preparation
Mice were sacrificed by cervical dislocation at the age
of 1 week, 8 weeks, 12 months, or when moribund.
The pancreas was isolated, blotted dry, and weighed
to the nearest milligram. Parts of the head, tail, and
central part of the pancreas were dissected, pooled,
frozen on dry ice, and stored at 80 °C. The remain-
ing tissue was fixed in 4% para-formaldehyde (PFA,
in PBS, pH 7.4) overnight and subsequently embedded
in paraffin for histopathological examination. From
mice sacrificed at the age of 1 week, the whole pan-
creas was either frozen on dry ice or immediately
homogenized in total in RLT buffer (Qiagen), freshly
supplemented with 1% beta-mercaptoethanol (Roth,
Karlsruhe, Germany) and shock-frozen in liquid nitro-
gen for RNA isolation, or incubated as a whole in 4%
PFA overnight and embedded in paraffin.
2.5. Immunohistochemistry
Immunohistochemistry was performed, using specific
antibodies for detection of murine (m) mBTC,
mTGFA, mAREG, mEREG, mACTA2, mEGFR,
cleaved caspase-3, and human (h) hBTC, hEGFR,
hERBB2, hERBB3, and hERBB4 in sections of PFA-
fixed, paraffin-embedded pancreatic tissue. For all
immunostainings, the slides were boiled in a pressure
cooker for 15 min in 10 mM sodium citrate buffer pH
6.0 or EDTA pH 9, blocked in 3% H2O2 for 30 min
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and in 5% of the appropriate serum for another
30 min. Primary antibodies were incubated over night
at 4 °C. After washing in PBS, the slides were incu-
bated with the appropriate secondary antibodies for
1 h at room temperature, and the signal was amplified
using the VECTASTAIN ABC HRP kit (Vector,
Burlingame, CA, USA) for 30 min at room tempera-
ture. As chromogen, ImmPACTTM DAB peroxidase
substrate kit (Vector) was used and the sections were
counterstained with hematoxylin (Roth) for 3 min. A
list of primary and secondary antibodies with the cor-
responding dilutions is provided in Table S2. Appro-
priate negative control sections (omission of the first
antibodies) were carried along in all IHC experiments.
2.6. Histopathology and morphometric analyses
For histological analyses, the PFA-fixed and paraffin-
embedded pancreas was serially sectioned and four
sections with a distance of nine sections between were
sampled and stained with hematoxylin and eosin
(H&E), and Masson’s trichrome, respectively. The sec-
tions were independently analyzed by two researchers
in a blinded fashion. (Pre-) neoplastic pancreas alter-
ations were classified, using established histomorpho-
logical criteria (Distler et al., 2014; Hruban et al.,
2004). For quantification of lesions, the relative section
areas of altered tissue in the pancreas were determined.
The fractional area of the total ‘reactive tissue’ (com-
prising fibrosis, inflammation, preneoplastic lesions,
including acinar-to-ductal metaplasia (ADM) and
PanIN of grades 1-3, as well as PDAC) in the pan-
creas was quantified in digital images covering the
complete area of all pancreas sections (2009 magnifi-
cation) of n = 4 mice of 8 weeks of age per group,
using LAS software version 3.8.0 (Leica Microsystems,
Wetzlar, Germany).
Additionally, the area density of acinar cell section
profiles, ADM, PanIN1-3, PDAC, and fibrosis in the
pancreas of 12-month-old mice (n = 4/group) was sep-
arately determined by point counting (Howard and
Reed, 2004; Weibel, 1979). For this, digital images of
H&E or Masson’s trichrome-stained sections were
superimposed with a grid of equally spaced crosses
(117 crosses/2 cm2), using NETSCOPE VIEWER software
(Net-Base Software GmbH, Freiburg, Germany).
Crosses hitting section profiles of the respective struc-
ture were counted and related to the number of crosses
hitting pancreas tissue in all examined sections per
case. On the average, 111  7 points were counted per
case. Data were analyzed by Student’s t-test, respec-
tively, by 2-way ANOVA and plotted as column bar
plots in GRAPHPAD PRISM (GraphPad Prism version 5.0
for Windows, GraphPad Software, San Diego, CA,
USA).
2.7. RAS activity assay
To evaluate pancreatic RAS activity, the Active Ras
Detection Kit (Cell Signaling, Frankfurt, Germany)
was used according to the manufacturer’s instructions.
In brief, dissected, frozen pancreas was homogenized
in lysis/binding/wash buffer, freshly supplemented with
phenylmethanesulfonyl fluoride, and 300 µg total pro-
tein was incubated with the GST-Raf1-Ras-binding
domain for 1 h at 4 °C, washed and eluted under
denaturing conditions and applied to an SDS-gel elec-
trophoresis using Mini-PROTEAN TGX Stain-
FreeTM Precast Gels (BIO-RAD, Hercules, CA, USA)
and subsequent Western blot analysis detecting mRAS.
Total protein was quantified using Image Lab 6.0.1
(Bio-Rad), and the amount of active RAS was refer-
enced to total protein and plotted in GRAPHPAD PRISM.
Data were analyzed by Student’s t-test.
2.8. Co-immunoprecipitation
Pancreata were homogenized in a TRIS-based buffer
(50 mM Tris, 150 mM NaCl, 1% NP-40, 10% glycerol,
1 M EDTA; freshly supplemented with protease, and
phosphatase inhibitors), and 350 µg of protein was
immunoprecipitated by targeting EGFR. For this, the
lysate was incubated with 1 µg of EGFR antibody
(Santa Cruz, SC-03, Heidelberg, Germany) or 1 µg of
normal IgG antibody (R&D Systems, Minneapolis,
MN, USA) at 4 °C overnight and incubated with
50 µL of protein A-coated magnetic beads (Cell Sig-
naling) for 30 min at room temperature. After wash-
ing, the precipitate was eluted under denaturing
conditions and applied to a western blot detecting
ERBB2 (Santa Cruz, SC-284), ERBB3 (Santa Cruz,
SC-285), and EGFR as control.
2.9. Western blot analysis
Pancreas of animals was homogenized in Laemmli-ex-
traction buffer as described previously (Dahlhoff et al.,
2015). Protein samples with equal concentrations were
electrophoresed on 10% polyacrylamide–sodium dode-
cyl sulfate gels and blotted to polyvinylidene difluoride
membranes (GE Healthcare, Munich, Germany). The
membranes were blocked with 5% milk and incubated
with the primary antibodies overnight at 4 °C. After
washing, the membranes were incubated in the appro-
priate horseradish peroxidase-conjugated secondary
antibody. Immunoreactive bands were visualized by
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chemiluminescence with an ECL Kit (GE Healthcare
or Thermo Scientific). Antibodies and dilutions are
supplied in Table S3. Densitometrical analyses were
performed with IMAGEJ 1.52a (http://rsb.info.nih.gov/ij)
and plotted in GRAPHPAD PRISM (GraphPad Prism ver-
sion 5.0).
2.10. Reverse transcriptase–PCR
RNA was extracted from different organs with TRI-
zol reagent (Invitrogen, Darmstadt, Germany), and
3 µg of RNA was reverse-transcribed in a final vol-
ume of 30 µL using RevertAid reverse transcriptase
(Thermo Scientific, Schwerte, Germany) according to
the manufacturer’s instructions. To show the qualita-
tive mRNA expression of Btc-KO mice, reverse tran-
scription–PCR (RT–PCR) was performed by using
reagents from Qiagen. The final reaction volume was
20 µL, and cycle conditions were 94 °C for 5 min,
followed by 35 cycles of 94 °C for 1 min, 58 °C for
1 min, and 72 °C for 1 min. The amplicon for Btc
was digested by PflMI (NEB, Frankfurt, Germany)
for 90 min at 37 °C and subject to agarose elec-
trophoresis to reveal the mutation side. Gapdh was
used as reference mRNA. The used primers are listed
in Table S1.
2.11. Hematoxylin and eosin (H&E) and
Masson’s trichrome staining
H&E-stainings (histological standard stain) and Mas-
son’s trichrome stainings (demonstration of collage-
nous connective tissue) were performed on sections of
PFA-fixed and paraffin-embedded pancreas tissue,
using standard protocols.
2.12. Cell culture and stimulation experiments
PANC-1 and BcPC-3 cells were purchased from CLS
(Cell Lines Service, Eppelheim, Germany) 4 months
before the experiments were performed. All human
permanent cell lines in the CLS cell bank were authen-
ticated by using the STR DNA profiling analysis.
Mycoplasma testing was done every 6 months for all
cultured cells, using a Mycoplasma Detection Kit
(PlasmoTest; InvivoGen, Toulouse, France). Both can-
cer cell lines were maintained at 37 °C and 5% CO2.
PANC-1 cells were cultured in Dulbecco’s modified
Eagle Medium (Merck, Darmstadt, Germany), BxPC-3
cells in Roswell Park Memorial Institute 1640 medium
(RPMI; Merck), both supplemented with 10% FBS
(Merck) and 1% Penicillin/Streptomycin (Merck). At a
confluence of 90%, cells were starved overnight (1%
FBS) and stimulated the next day with 50 ngmL1 of
recombinant human BTC (rhBTC; R&D Systems
#261-CE) for 5 and 15 min. Cells were then lysed in a
Tris-based buffer [50 mM Tris, 150 mM NaCl, 1% NP-
40, 10% glycerol, 1 M EDTA; freshly supplemented
with protease and phosphatase inhibitors (Roche,
Penzberg, Germany)] and subject to western blot anal-
ysis detecting phosphorylation and total expression of
the ERBB receptors.
2.13. 3D primary cell culture
3D primary cell cultures of pancreatic acini were pre-
pared according to a modified protocol of Qu and
Konieczny (2013). For isolation of acini, freshly dis-
sected pancreata of 3-week-old wild-type mice were
washed twice in sterile ice-cold PBS and immediately
minced and digested twice in collagenase P solution
(Hanks Balanced Salt Solution; Sigma, Taufkirchen,
Germany), 5% FBS, 0.2 mgmL1 soybean trypsin
inhibitor (STI; Sigma), 0.2 mgmL1 Collagenase P
(Roche) at 37 °C for 10 min. The pancreatic tissue
was gently pressed and washed through a 100-µm cell
strainer and incubated in red blood cell lysis buffer
(Roth) for 10 min at 37 °C. The acini recovered for
1 h in 3D culture medium [RPMI 1640, 1% FBS, 1%
Penicillin/Streptomycin, 1 mgmL1 STI, 1 µgmL1
dexamethasone (Sigma)]. Prior to cell seeding, the cul-
ture dishes were coated with a matrix of rat tail colla-
gen I (Invitrogen, Carlsbad, CA, USA) and RPMI
medium, supplemented with NaHCO3 for at least 1 h
at 37 °C. For seeding, the cell suspension was mixed
with the collagen I coating gel in a ratio 1 : 3, gently
placed into the coated dishes, and solidified for 1 h at
37 °C, 5% CO2. The matrix was then coated with
warm 3D culture medium and stimulated or left
untreated. For stimulation experiments, 3D culture
medium was supplemented with rhBTC or rhTGFA or
left untreated and investigated under a light micro-
scope at days 0, 4, and 5 after treatment. The number
of transdifferentiated cells was estimated by two
researchers, independently.
2.14. Statistics
Data are presented as means  SEM and compared
by two-tailed unpaired Student’s t-test, and in the case
of more than two groups by analysis of variance
(ANOVA) and Tukey’s multiple comparison test. All
data were analyzed with GRAPHPAD PRISM (GraphPad
Prism version 5.0 for Windows, GraphPad Software,
San Diego, CA, USA). P-values < 0.05 were consid-
ered statistically significant.
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3. Results
3.1. BTC and the ERBB receptors are expressed
in human pancreas, PDAC samples, PDAC cell
lines, and in pancreata of PDAC mice
Betacellulin was detected by IHC predominantly in the
islets of Langerhans and in ducts and acini of normal
human pancreas (hNP), in all examined human PDAC
samples (6/6), in cancer cells, and the adjacent stroma
(Fig. 1A). Western blot analysis revealed BTC expres-
sion in 5/6 hPaCaCells (Fig. 1C). Furthermore, all
ERBB receptors were detected by IHC in human
PDAC (Fig. 1E). Since BTC can activate all ERBB
receptors, either directly or indirectly, we evaluated the
phosphorylation status of all ERBB receptors upon
BTC stimulation in two hPaCaCells. Stimulation of
PANC-1 (with KRAS mutation) and BxPC-3 (with
wild-type KRAS) cells with hBTC led to the activation
of all receptors at 5 and 15 min, while ERBB3 was
constitutively activated in both cell lines (Fig. 1D).
These data indicate that BTC and the ERBB receptors
are associated with human PDAC. The pancreata of
Ptf1acre/+;KrasG12D/+ (herein referred to as KC) mice
revealed a strong positive immunostaining for endoge-
nous BTC expression in low- and high-grade PanIN in
5/6 samples (Fig. 1B).
3.2. Lack of BTC in KC mice results in a
reduction of tumor burden and decreased EGFR
phosphorylation
To evaluate the function of BTC in PDAC develop-
ment, we generated a BTC knockout mouse (BTC/)
by CRISPR/Cas9 (clustered regularly interspaced short
palindromic repeats/CRISPR-associated 9) technology
(Fig. S1A). BTC/ mice were viable and showed no
macroscopic phenotype, and bred in a Mendelian ratio
(data not shown). RT–PCR analysis confirmed the fra-
meshift in exon 2 of the Btc gene (Fig. S1B), and the
loss of BTC was confirmed by IHC (Fig. S1D).
Crossed into the KC background (herein referred to as
B/KC mice), B/KC mice showed no differences in
body and relative pancreas weight at the age of
8 weeks and 12 months, respectively (Fig. S1C). All
B/KC animals remained clinically unremarkable to
the time of dissection at 12 months, while KC mice
started deceasing already at 7 months (Fig. 2A). The
fractional section area of reactive tissue (fibrosis,
inflammation, ADM, PanIN) in the pancreas was
determined in 8-week-old mice. At this age, B/KC
mice showed a significant 10-fold decrease in area
densities of reactive tissue in the pancreas as compared
to KC mice (Fig. 2B,C), indicating a decelerated
PDAC development. In pancreata of 12-month-old
mice, we observed decreased PDAC progression upon
BTC depletion. Compared to KC mice, B/KC mice
displayed higher area densities of preneoplastic lesions
(ADM, PanIN1-2) in the pancreas, whereas the frac-
tional section areas occupied by PDAC were signifi-
cantly decreased (Fig. 2F,G). Western blot analysis
revealed reduced EGFR expression and phosphoryla-
tion in pancreata of 8-week-old (Fig. 2D,E) and
reduced EGFR phosphorylation in 12-month-old
(Fig. 2H,I) B/KC mice compared to age-matched
KC mice. These data indicate that the depletion of
BTC attenuates tumor initiation and progression by
downregulating EGFR signaling, which results in a
prolonged survival.
3.3. Overexpression of BTC in KC mice leads to
early onset of PDAC and a high mortality
To investigate how BTC influences PDAC, we over-
expressed BTC in a murine PDAC model. We
crossed ubiquitously overexpressing BTC mice into
the KC background (Ptf1acre/+;KrasG12D/+;Btctg/+,
herein referred to as BKC mice). BKC mice devel-
oped cachexia after 6 weeks and lost up to 25% of
their body weight within the following 2 weeks
(Fig. 3A). The major cohort of BKC mice (13/18)
was dead at 2 months (median survival: 2.75 months),
whereas KC mice had a median survival of
11 months (Fig. 3B). H&E staining of pancreata of
1-week-old mice of both groups appeared normal
(Fig. 3C). Already at the age of 4 weeks, up to two
thirds of the BKC pancreata were covered by inflam-
mation, fibrosis, ADM, and low-grade PanIN, while
these structural abnormalities were rarely observed in
age-matched KC pancreata (Fig. 3C). At 8 weeks of
age, reactive lesions occupied only a minor portion of
pancreas sections in KC mice (Fig. 3C). In contrast,
the pancreas parenchyma of age-matched BKC mice
was consistently replaced completely by low- and
high-grade PanIN and invasive carcinoma accompa-
nied by a marked desmoplastic reaction. Desmoplasia
was indicated by alpha-smooth-muscle-actin (ACTA2)
staining (Fig. 3D), detecting activated pancreatic stel-
late cells and by Masson’s trichrome staining reveal-
ing massive amounts of collagen fibers in BKC
animals compared to age-matched KC mice (Fig. 3E).
75% of KC mice developed high-grade PanIN and
carcinoma during their lifetime, while all BKC mice
had developed carcinomas already at the age of
8 weeks.
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Fig. 1. BTC and the ERBBs are expressed in human pancreas, PDAC samples, in human PDAC cell lines, and in pancreata of KC mice. (A)
Immunohistochemical detection of BTC in hNP and in human PDAC specimen. (B) Immunohistochemical detection of BTC, TGFA, AREG,
and EREG in PanIN of KC mice. Scale bars in A and B: 100 µm. (C) Western blot analysis of BTC expression in hPaCaCells. TUBA1A served
as a reference protein. (D) Western blot analysis of ERBB receptor expression and phosphorylation in PANC-1 cells and BxPC-3 cells after
BTC stimulation. GAPDH served as reference protein. (E) IHC of all ERBB receptors on hNP and hPDAC. Scale bars: 50 µm.
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3.4. BTC activates ERBB receptors, enhances
RAS activity, and induces ADM
We investigated ERBB receptor phosphorylation by
Western blot analysis upon BTC overexpression in KC
mice at the age of 1 week, when pancreatic tissue
sections of KC mice did not yet exhibit histomorpho-
logical evidence of ADM alterations and displayed a
homogenous cellular composition. BTC overexpression
in KC mice resulted in the activation of EGFR,
ERBB2, and ERBB4. ERBB3 phosphorylation was














































































































































































Fig. 2. Characterization of B/KC mice. (A) Kaplan–Meier curve demonstrating the survival of KC and BKC mice. (B) Representative H&E
stainings of pancreata of 8-week-old B/KC mice compared to age-matched KC littermates, typical lesions are indicated by arrowheads. (C)
Morphometric analysis of reactive tissue in the pancreas of 8-week-old B/KC and KC mice. Data were analyzed by Student’s t-test. (D)
Western blot analysis and (E) corresponding densitometrical analyses showing EGFR expression and phosphorylation in pancreata of 8-
week-old B/KC mice compared to age-matched KC pancreata. GAPDH served as reference protein. (F) Representative H&E stainings of
pancreata of 12-month-old mice, typical lesions are indicated by arrowheads. (G) Histopathological grading of pancreata of 12-month-old
mice. (H) Western blot and (I) densitometrical analysis of pancreata of 12-month-old mice showing EGFR expression and phosphorylation in
B/KC mice compared to KC mice. Scale bars: 100 µm. Data are presented as means  SEM. *P < 0.05, **P < 0.01.
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were similar in both groups (Fig. 4A,B). To evaluate
the receptor dimerization behavior upon BTC activa-
tion, we performed co-immunoprecipitations. In BKC
mice, EGFR bound ERBB2, but not ERBB3. KC
mice had much less EGFR/ERBB2 dimers, even when
the reduced amount of pulled-down EGFR protein
was considered. Due to the high heterogeneity of tissue
composition in pancreata of BKC mice at the age of
8 weeks, we compared tumors of 8-week-old BKC
mice with tumors of 12-month-old KC mice, which
presented a similar tumor burden. The amount of
EGFR/ERBB2 dimers in KC pancreata was again
lower compared to BKC mice (Fig. 4C). ERBB3 did
not bind to EGFR at any age. There are several ways
for BTC to accelerate PDAC development. KRASG12D
is the initiating mutation in PDAC, but the latency for
tumor development is very long, and often additional
stimuli are necessary to induce RAS-dependent trans-
formation of normal tissue (Carriere et al., 2009; Hin-
gorani et al., 2003; Ji et al., 2009). We assumed that
BTC could be a driver of RAS activity to accelerate
tumor development. A RAS-activity assay of
pancreata of 8-week-old KC mice and BKC mice
revealed that BKC mice harbor a significantly higher
amount (threefold) of active RAS compared to KC
mice (Fig. 4D,E). To investigate which receptors trans-
mit BTC-induced RAS activation, we studied RAS
activity in the pancreata of BKC mice with a depletion
of either EGFR (E1KO;BKC), ERBB2 (E2KO;BKC),
or ERBB4 (E4KO;BKC). Notably, BTC-mediated
RAS activity was exclusively transmitted by EGFR
(Fig. 4F). Also crucial for PDAC is ADM develop-
ment. Since it is known that BTC regulates (trans-)
differentiation in numerous cells (Li et al., 2005; Paz
et al., 2011; Yoshida et al., 2002), we assumed that
BTC might be involved in transdifferentiating acinar
to duct cells, thereby promoting the accelerated onset
of PDAC observed in BKC mice. We isolated wild-
type murine acinar cells, embedded them into a 3D
collagen matrix and stimulated with BTC or TGFA
for 5 days. While wild-type cell clusters did not show
signs of transformation, the majority of BTC-stimu-
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Fig. 3. BTC induces adverse events in KC mice. (A) Body weight curve of BKC mice compared to KC littermates. Data were analyzed by 2-
way ANOVA. (B) Kaplan–Meier curve depicting the survival of BKC mice compared to KC mice. Data were analyzed using a log-rank test.
(C) H&E staining of pancreata of 1-, 4- and 8-week-old KC and BKC mice. (D) Representative immunohistochemical detection of ACTA2 in
pancreata of 8-week-old KC and BKC mice. (E) Masson’s trichrome staining of pancreata of 8-week-old KC and BKC mice depicting
connective tissue in BKC mice. Scale bars: 100 µm. Data are presented as means  SEM. *P < 0.05, ***P < 0.001.
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3.5. ERBB2 and ERBB4 affect the tumor burden
in BKC mice
Betacellulin signaling is mediated by EGFR-activated
RAS activity, but it remains unknown whether ERBB2
and ERBB4 are involved in BTC-mediated develop-
ment of PDAC. We therefore generated BKC mice
with a pancreas-specific knockout of ERBB2 or of
ERBB4 (E2KO;BKC and E4KO;BKC, respectively).
The lack of pancreatic ERBB2 or ERBB4 expression
in the BKC mouse showed distinct effects: While all
groups grew similarly until week 6 after birth, E2KO;
BKC mice had a significantly reduced body weight
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Fig. 4. BTC activates ERBB receptors, enhances RAS activity, and induces ADM. (A) Western blot and (B) corresponding densitometrical
analysis showing the phosphorylation of EGFR, ERBB2, ERBB3, and ERBB4 in pancreata of 1-week-old BKC mice compared to age-
matched KC mice. GAPDH served as reference protein. Data were analyzed by 2-way ANOVA with Bonferroni post-test. (C) Co-
immunoprecipitation of EGFR and indicated receptors in lysates of pancreata of 8-week-old and 12-month-old mice with different genotypes.
(D) RAS activity assay with (E) corresponding densitometrical analysis illustrating the abundance of active RAS protein in pancreata of KC
mice upon BTC overexpression. Total protein (TP) served as reference. Data were analyzed with Student‘s t-test. (F) RAS activity assay
comparing pancreata of BKC, E1KO;BKC, E2KO;BKC, and E4KO;BKC mice. (G) 3D primary tissue culture of acinar cells of 3-week-old wild-
type mice, treated with BTC compared to untreated cells (Co). Arrowheads indicate duct formation. Scale bars: 100 µm. PD, pull down, IB,
immunoblot, GST-RAF-RAS-BD, glutathione-S-transferase-RAF-RAS-binding domain. Data are presented as means-SEM. *P < 0.05,
**P < 0.01, ***P < 0.001.
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a significantly increased body weight compared to
BKC littermates (Fig. 5A), predicting a better outcome
for mice with an ERBB4 depletion. Indeed, the
Kaplan–Meier curve depicts, with a median survival of
15 months, the longest survival in E4KO;BKC mice.
Also E2KO;BKC mice present—with a median sur-
vival of 12.5 months—a significantly prolonged sur-
vival compared to BKC mice (median survival:
2.75 months) (Fig. 5B), indicating oncogenic functions
for both receptors. The relative pancreatic weight of
E2KO;BKC mice was decreased compared to that of
BKC mice at the age of 8 weeks (P = 0.059) (Fig. 5C,
left panel) and was similarly lower in moribund mice
(Fig. 5C, right panel). The H&E (Fig. 5D, left panel)
and Masson’s trichrome (Fig. 5D, right panel) staining
of E4KO;BKC pancreata revealed a penetration of
cancer cells similar to BKC mice, presenting with
fibrosis, PanIN, and carcinoma, while the lack of
ERBB2 rather resembled atypical flat lesions mixed
with ADM and low-grade PanIN, with an equal
amount of fibrosis in BKC pancreata, but with
decreased area of (pre-)neoplastic tissue, and remain-
ing acinar tissue was frequently observed. Western blot
analysis revealed that the loss of ERBB4-induced
changes in the ERBB signaling network (Fig. 5E,F).
The lack of ERBB4 resulted in significantly decreased
EGFR and ERBB2 phosphorylation, and it induced
enhanced ERBB3 activation. Further, the lack of
ERBB4 resulted in a significant downregulation of
mitogen-activated protein kinase 1/3 (MAPK) and
stress-activated protein kinase (SAPK) signaling. In 1-
week-old mice, EGFR activation was significantly
enhanced in E4KO;BKC pancreata, and also MAPK
activation was increased (Fig. S2A,B). Compared to
the knockout of ERBB4, the lack of ERBB2 only
resulted in significantly decreased SAPK signaling and
in decreased EGFR phosphorylation (P = 0.055).
However, no significant compensation of other ERBB
receptors was observed (Fig. S3A,B). Despite
decreased SAPK signaling, acinar cells of E2KO;BKC
mice demonstrated cleaved caspase-3 positivity in
immunostainings (Fig. S3C).
3.6. The loss of EGFR almost fully rescues the
BTC-mediated phenotype in 8-week-old KC mice
We deleted EGFR (E1) specifically in the pancreas
and revealed that EGFR-depleted BKC mice (E1KO;
BKC) had increased body weights, indicating a better
physical condition at the age of 2 and 12 months com-
pared to BKC mice (Fig. 6A, left panel). 100% of
E1KO;BKC mice were still clinically unremarkable at
the time of dissection (12 months), indicating a
drastically prolonged survival compared to BKC mice
(data not shown). Their relative pancreas weights were
significantly decreased in 8-week-old and increased in
12-month-old mice compared to BKC mice (Fig. 6A,
right panel), implying a better physical condition. His-
tology analysis revealed only moderate alterations in
E1KO;BKC mice, comprising multiple foci presenting
ADM (H&E, Fig. 6B), but with a complete lack of
fibrosis, shown by Masson’s trichrome staining to pan-
creata of BKC mice (Fig. 6B). ADM in 8-week-old
mice did not occur due to incomplete homologous
recombination of the EGFR locus, as observed in
Ardito et al. (2012) and Navas et al. (2012), as we veri-
fied this possibility in the negative immunostaining tar-
geting EGFR (Fig. 6E). However, ADM was positive
for ERBB2, ERBB3, and ERBB4 (Fig. 6E). Interest-
ingly, Western blot analysis revealed that the lack of
EGFR is accompanied by a decrease in phosphoryla-
tion and expression of ERBB2, ERBB3, and full-
length ERBB4 (Fig. 6C,D). However, we revealed that
the ICD of ERBB4 was highly phosphorylated in the
pancreata of E1KO;BKC mice compared to BKC mice
indicating compensatory ERBB4 signaling for ADM
development upon the loss of EGFR (Fig. 6C,D).
4. Discussion
While EGFR is crucial for the development of onco-
genic KRAS-induced PDAC development (Ardito
et al., 2012; Navas et al., 2012), targeting EGFR is
beneficial only for a small subset of patients (Moore
et al., 2007). Since EGFR is only one member of a
family of four receptor tyrosine kinases, either working
autonomously or as partner of ERBB2, ERBB3, or
ERBB4, we assumed that the remaining ERBB recep-
tors may have been underestimated in recent years and
could also play an important role in PDAC, particu-
larly, because ERBB ligands specific for ERBB4 have
been implicated in PDAC development or progression
(Chaturvedi et al., 2007; Ito et al., 2001; Ray et al.,
2014; Zhu et al., 2000). To assess the role of ERBB
ligands in PDAC, we deleted BTC in the KC mouse
model and revealed that the initiation and progression
of PDAC was decelerated. A 100% rate of viable B/
KC mice at the age of 12 months also suggests
increased survival rates. The benefits of BTC deletion
might stem from decreased EGFR expression and
phosphorylation levels observed in B/KC pancreata
at 8 weeks and decreased EGFR phosphorylation at
12 months. It was quite unexpected that the deletion
of a single ERBB ligand can modulate EGFR regula-
tion and PDAC progression to such an extent, as in
human and in murine PDAC almost all seven EGFR
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ligands are expressed abundantly and could arguably
compensate the loss of one single ligand. At the age of
8 weeks, BKC pancreata presented PDAC and desmo-
plasia and BKC mice displayed a decrease in the med-
ian survival of almost 9 months compared to KC
mice. Our study shows that besides TGFA (Siveke
et al., 2007) and HBEGF (Ray et al., 2014), BTC is
also highly involved in PDAC development and pro-
gression. KC mice have a long latency to develop
tumors and although all pancreatic cells are equipped
with mutated KRAS, only a subset of cells develops
lesions and, at low frequency, invasive PDAC (Hingo-
rani et al., 2003). Numerous studies suggest that the
additional loss of tumor suppressors (Hingorani et al.,
2005) or that other secondary events, for example,
pancreatitis (Carriere et al., 2009) or incidences
increasing KRASG12D activity above a certain thresh-
old (Ji et al., 2009) are required to initiate tumorigene-
sis. BTC could be such a factor which enhances RAS




















































































Fig. 6. The lack of EGFR in BKC mice revealed major changes in body weight, histology, and ERBB signaling. (A) Body and relative
pancreas weights of E1KO;BKC mice compared to BKC mice. Data were analyzed by ANOVA and Tukey’s multiple comparison test.
(B) Representative H&E (left panel) and Masson‘s trichrome (right panel) stainings of pancreata of BKC mice and E1KO;BKC mice. (C)
Western blot analysis and (D) corresponding densitometrical analysis showing the phosphorylation and expression of ERBB2, ERBB3, and
full-length ERBB4, and the phosphorylation of the ERBB4-ICD. CDH1 served as reference protein. Data were analyzed by ANOVA and
Tukey’s multiple comparison test. (E) Immunohistochemical detection of EGFR, ERBB2, ERBB3, and ERBB4 of pancreas samples of 8-
week-old E1KO;BKC mice. Scale bars: 100 µm. ***P < 0.001.
Fig. 5. ERBB2 and ERBB4 affect the tumor burden in BKC mice. (A) Body weight curves all groups. Data were analyzed by 2-way ANOVA.
(B) Kaplan–Meier curve depicting the survival of E2 KO;BKC and E4 KO;BKC mice compared to BKC mice. Data were analyzed by log-rank
test. (C) Relative pancreatic weight of all groups of 8-week-old mice (left panel) and of 12-month-old mice (right panel) compared to E2KO;
BKC, E4KO;BKC, and KC mice. Data were analyzed by ANOVA and Tukey’s multiple comparison tests. (D) Histology of BKC mice compared
to E2KO;BKC and E4KO;BKC mice at 8 weeks represented by H&E (left panel) and Masson’s trichrome staining (right panel). (E) Western
blot analysis with (F) corresponding densitometrical analysis comparing pancreata of 8-week-old BKC mice to E4KO;BKC littermates. Data
were analyzed by ANOVA and Tukey’s multiple comparison tests. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bars: 100 µm.
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progression of PDAC. Although BTC activates
EGFR, ERBB2, and ERBB4, the increase in RAS
activity is mediated by EGFR only, indicating a
dependency of RAS activity on EGFR-homodimeriza-
tion instead of heterodimerization with ERBB2 or
ERBB4. It is not surprising that EGFR is a crucial
player in KRAS-mediated tumorigenesis, since it was
previously shown that mice do not develop oncogenic
KRAS-driven PDAC in an EGFR-depleted back-
ground (Ardito et al., 2012; Navas et al., 2012). EGFR
is crucial for acinar cells to transdifferentiate into duct
cells. The EGFR ligands TGFA and HBEGF have
been previously implicated in this process (Ray et al.,
2014). BTC has a differentiation potential in many
other cell types (Li et al., 2005; Mashima et al., 1996;
Paz et al., 2011; Watada et al., 1996; Yoshida et al.,
2002), and we found that BTC is also able to transdif-
ferentiate wild-type acinar cells into duct cells. How-
ever, BTC transgenic mice never developed ADM at
any age. Thus, we consider BTC is not an oncoprotein
per se; however, it seems to act primarily as a trigger
for tumorigenesis in the examined mouse models.
While the importance of EGFR in PDAC is well-
established, the role of ERBB2 and ERBB4 is dis-
cussed controversially. ERBB2 mRNA was reported to
be expressed in 100% of PDAC samples with
increased protein expression compared to normal pan-
creas (Kolb et al., 2007), but another study reported
overexpression of ERBB2 in PDAC only at low fre-
quencies (Yan et al., 2014). Although ERBB2 amplifi-
cation was not associated with the outcome of PDAC
in a meta-analysis (Li et al., 2016), another study cor-
related the overexpression of ERBB2 with an aggres-
sive phenotype (Thybusch-Bernhardt et al., 2001).
However, to our knowledge, no functional studies
regarding ERBB2 in PDAC exist, and attempts to tar-
get ERBB2 were rather disappointing (Harder et al.,
2012). The deletion of Erbb2 in BKC mice resulted in
a significantly prolonged survival, which can be
explained by decelerated PDAC development. Since
ERBB2 heterodimerizes with EGFR, it is not surpris-
ing that ERBB2 depletion has a beneficial effect in
BKC mice. The delay in PDAC progression might be
explained by a decrease in EGFR and SAPK signal-
ing. SAPK activity was decreased in ERBB2-depleted
BKC mice, albeit it cannot be associated with
decreased apoptosis rates, since cleaved caspase-3 posi-
tivity rather indicated enhanced apoptosis compared to
BKC mice. Possibly, decreased SAPK signaling acts
via transcriptional regulation rather than by regulating
apoptosis.
The ambivalence of ERBB4 in PDAC, as in many
other cancers, has emerged from studies assessing
tumor-suppressive functions for the receptor, in that
ERBB4 expression was low in PDAC tissues and hPa-
CaCells (Kolb et al., 2007) and decreased in non-
metastatic tumors (Graber et al., 1999). Other studies
showed that a constitutively active ERBB4 homodimer
mutant inhibited colony formation in a pancreatic can-
cer cell line (Mill et al., 2011), and classified ERBB4 as
a potential oncogene, after revealing enhanced anchor-
age-independent growth of hPaCaCells by the stimula-
tion of ectopic ERBB4 expression (Mill et al., 2011).
We also attribute ERBB4 an oncogenic function, since
its knockout prolonged the survival of BKC mice
enormously. The majority of BKC mice lacking
ERBB4 showed histopathological pancreatic lesion
patterns comparable to BKC mice, which is not in line
with the survival outcome. ERBB4-depleted BKC mice
revealed decreased EGFR activity, MAPK-, and
SAPK-signaling. Decreased MAPK activation is not
simply explained by decreased EGFR signaling, since
this pathway was not affected by the loss of ERBB2,
where we also detected reduced EGFR activity. Thus,
these changes must be specific to ERBB4 depletion.
Considering that E4KO;BKC mice did not show a
reduction in RAS activity, it is surprising that they
show reduced MAPK signaling, which acts down-
stream of RAS. The ERBB4 depletion might result in
a considerable change in the downstream targets of
RAS. The reduction in MAPK signaling might result
in a reduced transcriptional activity of its target genes,
thereby acting in an antitumorigenic way. In 1-week-
old mice, we detected enhanced EGFR and MAPK
activity in ERBB4-depleted BKC mice, indicating that
EGFR/MAPK is involved in PDAC induction rather
than in PDAC progression. This also supports the the-
sis of EGFR-dependency in tumorigenisis in KC mice,
but the compensatory mechanism indicates a role for
ERBB4 in PDAC initiation, too. It furthermore sug-
gests the causality of EGFR and MAPK activity in an
ERBB4-dependent manner. Possibly, MAPK signaling
is preferably regulated by EGFR/ERBB4 heterodi-
mers, independent of ERBB2. Although EGFR signal-
ing was decreased, apparent histopathologic changes
were not detected. Increased ERBB3 activation possi-
bly compensates, in part, the loss of EGFR/ERBB4
signaling.
The deletion of EGFR resulted in a nearly complete
reversion of the BKC phenotype. However, in 8-week-
old BKC mice lacking EGFR, ADM lesions were
observed multifocally and were verified to be EGFR-
negative, but ERBB2-, ERBB3-, and ERBB4-positive,
indicating that, when the receptor family is challenged,
other receptors take over to induce ADM. Interest-
ingly, the lack of EGFR was accompanied by the
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downregulation of ERBB2, ERBB3, and full-length
ERBB4, but it induced ERBB4-ICD signaling, indicat-
ing a compensatory mechanism upon the loss of
EGFR. Possibly, the ERBB4-ICD is responsible for
ADM development in EGFR-depleted BKC mice,
since all remaining receptors expressed in the ADM
lesions were less phosphorylated. These findings are in
line with a study that associated BTC with resistance
to EGFR treatment in breast cancer cell lines (Kong
et al., 2008). The treatment with tyrosine kinase inhibi-
tors led to acute BTC expression, induction of
ERBB2/ERBB4 dimers, and ERBB4 cleavage, thereby
evading EGFR inhibition and reactivating EGFR-me-
diated signaling cascades. This is partially in line with
our results regarding ERBB4 activation and ERBB4-
RIP upon BTC activation in an EGFR-depleted
PDAC mouse model. This compensational mechanism
of the ERBB family could possibly play a role in the
resistance of an EGFR inhibitor therapy in PDAC
patients and in attenuated PDAC development in
EGFR/TP53-depleted KC mice (Ardito et al., 2012;
Navas et al., 2012).
5. Conclusions
We have shown that the depletion of BTC ameliorates
the outcome of PDAC and, conversely, that BTC
overexpression deteriorates PDAC prognosis in KC
mice. BTC involves not only EGFR activation, but it
also harnesses its ’partners in crime’ to induce acceler-
ated PDAC development and progression. BTC
enhances RAS activity, thereby potentially transform-
ing acinar to duct cells. The partial disease rescue
upon loss of ERBB2 and ERBB4 implies that both
receptors are potent oncogenes in PDAC. Especially,
enhanced ERBB4-ICD activation upon EGFR deple-
tion points to a compensatory behavior of the ERBB
family, thus emphasizing their role as co-targets for
combinatorial EGFR-targeted therapies. Our data
endorse that the pan-ERBB inhibitor dacomitinib exhi-
bits stronger antitumor effects than conventional sin-
gle-receptor targeting of PDAC cells (Momeny et al.,
2019). We suggest that targeting the complete ERBB
family, instead of a single receptor, might be promising
for future custom PDAC therapy development.
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